Limits...
A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.

Janić M, Lunder M, Šabovič M - Biomed Res Int (2015)

Bottom Line: We have developed a new "drug" and approach that appear to be effective in reducing arterial age.In addition, we have also implemented a new, innovative therapeutic approach, consisting of intermittent (cyclic) treatment-alternating short "treatment" periods and much longer "rest" periods (when the beneficial effects are still present but gradually decline).This new "drug" and approach both merit further investigation in order to confirm their antiaging efficacy.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Diseases, University of Ljubljana Medical Centre, Zaloška Cesta 7, 1000 Ljubljana, Slovenia.

ABSTRACT
We have developed a new "drug" and approach that appear to be effective in reducing arterial age. This "drug" represents a low, subtherapeutic dose of statin and sartan and particularly their low-dose combination. The improvement of arterial wall characteristics, also reflecting in a decrease of arterial age, was achieved after a short period of treatment (one month) with the above-mentioned drugs. In addition, we have also implemented a new, innovative therapeutic approach, consisting of intermittent (cyclic) treatment-alternating short "treatment" periods and much longer "rest" periods (when the beneficial effects are still present but gradually decline). This new "drug" and approach both merit further investigation in order to confirm their antiaging efficacy.

Show MeSH
A scheme representing the intermittent approach. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4363554&req=5

fig2: A scheme representing the intermittent approach. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline.

Mentions: We have tested this intermittent cycling approach in several studies. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline (Figure 2). We observed that the so-called “rest” period should be shorter in participants with already injured arterial wall (patients with diabetes mellitus, after myocardial infarction) and longer in healthy persons [7]. This observation is quite logical and supports our idea.


A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.

Janić M, Lunder M, Šabovič M - Biomed Res Int (2015)

A scheme representing the intermittent approach. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4363554&req=5

fig2: A scheme representing the intermittent approach. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline.
Mentions: We have tested this intermittent cycling approach in several studies. The approach consists of a short (one-month) treatment period followed by a relatively much longer rest period (from a few to 12 months). During the rest period, the beneficial effects are still present but gradually decline (Figure 2). We observed that the so-called “rest” period should be shorter in participants with already injured arterial wall (patients with diabetes mellitus, after myocardial infarction) and longer in healthy persons [7]. This observation is quite logical and supports our idea.

Bottom Line: We have developed a new "drug" and approach that appear to be effective in reducing arterial age.In addition, we have also implemented a new, innovative therapeutic approach, consisting of intermittent (cyclic) treatment-alternating short "treatment" periods and much longer "rest" periods (when the beneficial effects are still present but gradually decline).This new "drug" and approach both merit further investigation in order to confirm their antiaging efficacy.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Diseases, University of Ljubljana Medical Centre, Zaloška Cesta 7, 1000 Ljubljana, Slovenia.

ABSTRACT
We have developed a new "drug" and approach that appear to be effective in reducing arterial age. This "drug" represents a low, subtherapeutic dose of statin and sartan and particularly their low-dose combination. The improvement of arterial wall characteristics, also reflecting in a decrease of arterial age, was achieved after a short period of treatment (one month) with the above-mentioned drugs. In addition, we have also implemented a new, innovative therapeutic approach, consisting of intermittent (cyclic) treatment-alternating short "treatment" periods and much longer "rest" periods (when the beneficial effects are still present but gradually decline). This new "drug" and approach both merit further investigation in order to confirm their antiaging efficacy.

Show MeSH